NIAID BAA January 2022

The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.

FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.

Read more
/0 Comments/by

Powered by CARB-X

Tyler Merkeley, CARB-X co-founder and program director for ASPR’s Biomedical Advanced Research and Development Authority, describes the drivers and next steps in creating a diverse portfolio Powered by CARB-X, one of the world’s largest public-private partnerships dedicated to accelerating development of innovative antibacterial drugs, diagnostics, and devices.

 

 

 

/0 Comments/by

New NIAID Funding Opportunity Announcement: Partnerships for Countermeasures Against Select Pathogens (R01)

Purpose: To solicit research applications for milestone-driven projects focused on preclinical development of lead candidate countermeasures (therapeutics, vaccines and related technologies, or diagnostics) against select NIAID Emerging Infectious Diseases/Pathogens.

Application Due Date: October 3, 2016

Budget: Direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs.

Total Award: ~4,000,000 over 5 years

 

 

To discuss this opportunity or to learn about other non-dilutive funding that may be relevant to your organization, send us a note and we’ll get in touch with you directly!

/0 Comments/by